Improvement of functioning in patients with schizophrenia: real‑world effectiveness of aripiprazole once‑monthly (REACT study)
Abstract Conclusions:Our work here showed that patients with schizophrenia, treated with AOM in everyday clinical conditions, may experience clinically
ציר הזמן בטיפול בסכיזופרניה
הטיפול התרופתי מסייע מאד בהפחתת תסמינים כמו מחשבות שווא והזיות, אך פחות יעיל בסיוע להפחתת תסמינים שליליים. ישנן מגוון
Real-world effectiveness of aripiprazole once-monthly REACT study: Pooled analysis of two noninterventional studies
Abstract Conclusions: Treatment with AOM for patients with schizophrenia appeared effective and safe under real-life conditions. להמשך קריאה Schöttle, D.,
Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial
Abstract Importance: Long-acting injectable antipsychotics (LAIs) can potentially reduce hospitalization risk by enhancing medication adherence but are rarely considered for
Effects of aripiprazole long-acting injectable antipsychotic on hospitalization in recent-onset schizophrenia
Abstract Objective Recent-onset schizophrenia (ROS) represents a critical period that can greatly influence the clinical course of schizophrenia. The
Short-acting antipsychotics or long-acting injectables? A treatment comparison in patients with schizophrenia
Abstract Aim This research aims to compare the efficacy and direct costs of short-acting oral antipsychotics and aripiprazole once-monthly (AOM)
The use of long-acting Aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: a report on global assessment of functioning and the WHO wellbeing index
Abstract Background: In this non-interventional study, the functionality and well-being of patients with schizophrenia with aripiprazole once-monthly (AOM) was
Patients With Early-Phase Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting Injectable Antipsychotics): Results From the Recruitment Phase of the PRELAPSE Trial
Abstract Objective: To document the acceptability of treatment with long-acting injectable (LAI) antipsychotic medication to early-phase schizophrenia patients as demonstrated
Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study
Abstract Background With previously established efficacy of aripiprazole once-monthly injectable formulation (AOM) in pre-registration randomized controlled trials, the current
Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
Abstract Background: In this study, the treatment of schizophrenia patients with aripiprazole once-monthly (AOM) was evaluated under real-life conditions
Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study
Abstract Objective To evaluate long-term safety and effectiveness of continued treatment with aripiprazole once-monthly 400 mg (AOM 400) in patients with schizophrenia. להמשך
Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics
Abstract Objective: To assess the effects of aripiprazole once-monthly 400 mg (AOM 400) on clinical symptoms and global improvement in
Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia
Abstract Objective To directly compare aripiprazole once-monthly 400 mg (AOM 400) and paliperidone palmitate once-monthly (PP) on the Heinrichs–Carpenter Quality-of-Life Scale (QLS), a validated
Improvement of functioning in patients with schizophrenia: real‑world effectiveness of aripiprazole once‑monthly (REACT study)
Abstract Conclusions:Our work here showed that patients with schizophrenia, treated with AOM in everyday clinical conditions, may experience clinically
ציר הזמן בטיפול בסכיזופרניה
הטיפול התרופתי מסייע מאד בהפחתת תסמינים כמו מחשבות שווא והזיות, אך פחות יעיל בסיוע להפחתת תסמינים שליליים. ישנן מגוון
Real-world effectiveness of aripiprazole once-monthly REACT study: Pooled analysis of two noninterventional studies
Abstract Conclusions: Treatment with AOM for patients with schizophrenia appeared effective and safe under real-life conditions. להמשך קריאה Schöttle, D.,
Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial
Abstract Importance: Long-acting injectable antipsychotics (LAIs) can potentially reduce hospitalization risk by enhancing medication adherence but are rarely considered for
Effects of aripiprazole long-acting injectable antipsychotic on hospitalization in recent-onset schizophrenia
Abstract Objective Recent-onset schizophrenia (ROS) represents a critical period that can greatly influence the clinical course of schizophrenia. The
Short-acting antipsychotics or long-acting injectables? A treatment comparison in patients with schizophrenia
Abstract Aim This research aims to compare the efficacy and direct costs of short-acting oral antipsychotics and aripiprazole once-monthly (AOM)
The use of long-acting Aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: a report on global assessment of functioning and the WHO wellbeing index
Abstract Background: In this non-interventional study, the functionality and well-being of patients with schizophrenia with aripiprazole once-monthly (AOM) was
Patients With Early-Phase Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting Injectable Antipsychotics): Results From the Recruitment Phase of the PRELAPSE Trial
Abstract Objective: To document the acceptability of treatment with long-acting injectable (LAI) antipsychotic medication to early-phase schizophrenia patients as demonstrated
Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study
Abstract Background With previously established efficacy of aripiprazole once-monthly injectable formulation (AOM) in pre-registration randomized controlled trials, the current
Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
Abstract Background: In this study, the treatment of schizophrenia patients with aripiprazole once-monthly (AOM) was evaluated under real-life conditions
Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study
Abstract Objective To evaluate long-term safety and effectiveness of continued treatment with aripiprazole once-monthly 400 mg (AOM 400) in patients with schizophrenia. להמשך
Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics
Abstract Objective: To assess the effects of aripiprazole once-monthly 400 mg (AOM 400) on clinical symptoms and global improvement in
Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia
Abstract Objective To directly compare aripiprazole once-monthly 400 mg (AOM 400) and paliperidone palmitate once-monthly (PP) on the Heinrichs–Carpenter Quality-of-Life Scale (QLS), a validated